Cryoport (MM) (NASDAQ:CYPT)
Historical Stock Chart
From May 2019 to May 2024
Calypte Biomedical Raises an Additional $1.5 Million in Private
Placement
PLEASANTON, Calif., July 13 /PRNewswire-FirstCall/ -- Calypte Biomedical
Corporation (OTC:CYPT) (BULLETIN BOARD: CYPT) announced today that it has
raised an additional $1.5 million in a private placement to accredited
investors. The Company has issued 3.7 million shares of its common stock at
$0.40 per share and five-year warrants to purchase 2.6 million shares of its
common stock at $0.50 per share. The proceeds are expected to be used
primarily for general working capital purposes.
The Company plans to file a registration statement in connection with the
private placement to register the shares of common stock issued and the shares
of common stock underlying the warrants granted.
About Calypte Biomedical:
Calypte Biomedical Corporation, headquartered in Pleasanton, California, is a
public healthcare company dedicated to the development and commercialization of
in vitro diagnostic tests, primarily for the detection of antibodies to Human
Immunodeficiency Virus (HIV), and other sexually transmitted and infectious
diseases. Calypte's currently marketed laboratory- based tests include an
enzyme immunoassay (EIA) HIV-1 antibody screening test and an HIV-1 antibody
western blot supplemental test, the only two FDA- approved HIV-1 antibody tests
for use on urine samples, as well as an FDA- approved serum HIV-1 antibody
western blot supplemental test. Calypte is actively engaged in developing new
test products for the rapid detection of HIV and other infectious diseases.
Calypte believes that there is a significant need for rapid detection of such
diseases globally to control their proliferation, particularly in
lesser-developed countries, which lack the medical infrastructure to support
laboratory-based testing. Calypte believes that testing for HIV and other
infectious diseases may make important contributions to public health.
Statements in this press release that are not historical facts are
forward-looking statements within the meaning of the Securities Act of 1933, as
amended. Those statements include statements regarding the intent, belief or
current expectations of the Company and its management. Such statements reflect
management's current views, are based on certain assumptions and involve risks
and uncertainties. Actual results, events, or performance may differ materially
from the above forward-looking statements due to a number of important factors,
and will be dependent upon a variety of factors, including, but not limited to,
the Company's ability to obtain additional financing and access funds from its
existing financing arrangements that will allow it to continue its current and
future operations and whether demand for its test products in domestic and
international markets will continue to expand. The Company undertakes no
obligation to publicly update these forward-looking statements to reflect
events or circumstances that occur after the date hereof or to reflect any
change in the Company's expectations with regard to these forward-looking
statements or the occurrence of unanticipated events. Factors that may impact
the Company's success are more fully disclosed in the Company's most recent
public filings with the U.S. Securities and Exchange Commission ("SEC"),
including its annual report on Form 10-KSB for the year ended December 31, 2003
and its subsequent filings with the SEC.
Company Contact:
Richard Brounstein, CFO
(925) 730-7200
email:
Investor Relations Contact:
Tim Clemensen,
Rubenstein Investor Relations
Phone: 212-843-9337
Email:
DATASOURCE: Calypte Biomedical Corporation
CONTACT: Richard Brounstein, CFO of Calypte Biomedical Corporation,
+1-925-730-7200, ; or Tim Clemensen of Rubenstein
Investor Relations, +1-212-843-9337, for Calypte
Biomedical Corporation
Web site: http://www.calypte.com/